The peptide research universe, mapped.
Peptide science moves faster than the evidence behind it, marketing claims outrun the trials, and regulatory status shifts from one quarter to the next.
Compound Universe Genome is an independent peptide research project that maps each compound’s evidence chain: mechanism of action, study model, human outcomes, safety signals, and regulatory status.
What CU-Genome specializes in
CU-Genome specializes in evidence tiering: separating what a laboratory assay showed from what a randomized controlled trial actually proved. The project is known for three things, and they are the reason the profiles read differently from the rest of the category.
Every claim is graded by study model. Every regulatory statement carries a date and a jurisdiction. Nothing on this site is for sale.
Primary literature
Claims trace to PubMed records, original DOIs, trial registries, and regulator documents, not to commercial summaries.
Evidence classified
In-vitro, animal, human, and regulatory findings stay in separate tiers and are never blended into one verdict.
Limits disclosed
Small samples, absent replication, surrogate endpoints, and missing long-term safety data stay visible on the page.
No peptide sales
An informational research project with no storefront, no vendor links, and no affiliate pricing.
Peptide research across biological systems
CU-Genome organizes the literature by biological system, because a compound’s evidence quality rarely travels between them. A peptide with human trial data for one outcome is often animal-only for another.
Healing and recovery
BPC-157, TB-500, and thymosin beta-4 research across tendon models, wound healing, angiogenesis, and gastrointestinal repair.
Weight and metabolism
GLP-1, GIP, and glucagon receptor agonism, obesity trials, glycemic control, appetite signaling, and body composition.
Skin and hair
GHK-Cu, copper peptides, collagen, extracellular-matrix biology, skin remodeling, and hair-follicle research.
Muscle and performance
Growth-hormone secretagogues, GHRH analogs, lean mass, exercise physiology, and recovery evidence.
Brain, sleep, and cognition
Semax, Selank, and DSIP research across neuroprotection, mood, circadian biology, and cognition.
Immune and inflammation
Thymosin alpha-1, KPV, and LL-37 across immune signaling, host defense, and preclinical inflammation models.
Sexual health
PT-141 and kisspeptin studies covering melanocortin signaling, desire, arousal, and reproductive biology.
Aging and longevity
Epithalon, MOTS-c, and SS-31 across cellular senescence, mitochondrial biology, and translational limits.
The compounds CU-Genome tracks
Semaglutide activates the GLP-1 receptor. Tirzepatide targets both the GIP and GLP-1 receptors. GHK-Cu binds copper and signals dermal fibroblasts. Sermorelin stimulates the pituitary through the GHRH receptor.
Each profile states the mechanism first, then the evidence behind it, then the regulatory position. Approved medicines, discontinued drugs, clinical-stage candidates, and research-only compounds are never presented as equivalent.
BPC-157Preclinical tissue-repair research
GHK-CuCopper tripeptide, matrix biology
TB-500Thymosin beta-4 fragment
TesamorelinGHRH analog, FDA-approved
SermorelinGHRH analog, 503A compoundable
IpamorelinSelective GH secretagogue
RetatrutideInvestigational triple agonist
SemaglutideGLP-1 receptor agonist
TirzepatideDual GIP and GLP-1 agonist
PT-141Melanocortin agonist, FDA-approved
Thymosin alpha-1Immune-modulating peptide
CJC-1295Long-acting GHRH analog
Different studies answer different questions
Evidence tiering is the whole method. A mechanism observed in cultured cells and an outcome measured in a phase 3 trial are not the same claim, and collapsing them is how most peptide content misleads.
In vitro
Experiments in cells, tissues, or isolated systems. They explore a mechanism and cannot establish a clinical effect.
Animal
Preclinical models that surface biological signals, safety concerns, or hypotheses requiring human validation.
Human
Observational studies, pharmacology research, and controlled trials, weighed by design quality and endpoint measured.
Regulatory
Approval labels, safety communications, and compounding decisions, each dated to its jurisdiction.
Research beyond efficacy
A benefits list is not research. Pharmacokinetics, comparative evidence, documented risk, and legal status decide whether a finding means anything in practice.
01 How peptides interact with biology
Receptor activity, signaling pathways, half-life, bioavailability, and metabolism, plus the gap between a plausible mechanism and a demonstrated outcome.
02 Like-for-like evidence
Compounds compared by molecular target, study population, evidence maturity, measured outcomes, and regulatory position.
03 Status with a date and jurisdiction
FDA approval, 503A and 503B compounding eligibility, research-use-only labeling, and WADA restrictions are separate questions that change.
04 Documented and unknown risks
Reported adverse events per compound, the size of the studies behind them, and the safety questions no trial has answered yet.
Evidence before excitement
Every summary shows what a study reports, how much confidence it earns, and what it cannot establish.
01 Start with primary literature
Original research, trial registries, PubMed records, DOIs, approved labels, and regulator documents outrank commercial summaries.
02 Label the evidence
Laboratory, animal, observational, controlled human, systematic-review, and regulatory findings are identified separately.
03 Report the limitations
Small samples, weak controls, surrogate outcomes, conflicts of interest, and absent replication stay visible.
04 Date material updates
New trials, approvals, safety communications, and regulatory decisions are folded in with a visible review date.
Start with the evidence, not the marketing.
Every compound profile opens with what is established, what remains unproven, and where the regulatory line sits today.
Compound Universe Genome covers peptide therapeutics and research peptides across solid-phase peptide synthesis, amino acid sequence and molecular weight, receptor binding, half-life and bioavailability, GHRH analogs and growth-hormone secretagogues, melanocortin agonists, randomized controlled trials, meta-analyses, phase 2 and phase 3 data, ClinicalTrials.gov registrations, FDA approval status, 503A and 503B compounding, Category 2 listings, Pharmacy Compounding Advisory Committee review, Federal Register notices, research-use-only labeling, and WADA prohibited-list status.
Medical and regulatory disclaimer: Compound Universe Genome is an independent educational resource, not a medical provider, pharmacy, laboratory, or peptide seller. Content is informational only and is not medical advice, diagnosis, treatment, or a recommendation to obtain or use any substance. Many compounds discussed are investigational or not approved for human use. Legal status varies by jurisdiction and changes over time. Consult a qualified, licensed clinician for medical decisions.